tbuckley/cabot-search huggingface dataset:
Fast-Track Schedule for Vitamin D3 Substitution in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Authors: Jonas Matthias Jabs, Viola Poeschel, Martin Sökler, Kerstin Habersang, Rolf Mahlberg, Ulrich Keller, Heinz-Gert Hoeffkes, Andreas Rank, Andreas Viardot, Andreas Neubauer, Marita Ziepert, Bettina Altmann, Stephan Stilgenbauer, Michael Pfreundschuh, Gerhard Held, Joerg Thomas Bittenbring
Journal: Blood (2020)
Enhanced Free Fatty Acid Uptake Via CD36 Promotes a Metabolic Switch to B-Oxidation within Hematopoietic Stem Cells in Response to Acute Infection
Authors: Jayna J Mistry, Jamie A Moore, Charlotte Hellmich, Aisha Jibril, Iain Macauley, Mar Moreno-Gonzalez, Federica Di Palma, Naiara Beraza, Kristian M Bowles, Stuart A Rushworth
Journal: Blood (2020)
Successful Clearance of Donor Specific Anti-HLA Antibodies after Desensitization with Rituximab, Velcade and Plasma-Exchange Followed By a Haploidentical Stem Cell Transplantion with Post-Transplantation Cyclophosphamide
Authors: Sabine Furst, Valerio Maisano, Agnes Basire, Angela Granata, Faezeh Legrand, Raynier Devillier, Samia Harbi, Luca Castagna, Christophe Picard, Claude Lemarie, Christian Chabannon, Didier Blaise
Journal: Blood (2020)
SAT0041 Validity of the application of a diagnostic protocol according to patterns of clinical presentation of uveitis to establish diagnosis
Authors: G Bonilla Hernán, S Muñoz Fernandez, V Hidalgo, J Fernandez Melón, A Schlincker, A Fonseca, F Gamero Ruiz, B Damas, E Martín Mola
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To validate the efficiency of the application of a diagnostic protocol based on the patterns of presentation of uveitis to establish the diagnosis. <h3>Methods</h3> Our Uveitis Clinic is composed of a multidisciplinary team of Ophatalmologists and Rheumatologist. We defined a clinical diagnostic protocol for the uveitis, based on the frequency of syndromes found in the literature in each clinical pattern of uveitis and the symptoms of the patients. We routinarelly performed a careful history, a complete ophtalmologic examination, hemogram, biochemistry, ESR, a fluorescent treponemal antibody absorption test, an urinary test and a chest X Ray. Other diagnostic procedures were ordered according to a established protocol based on the clinic patterns of presentation of uveitis. Data from the patients were prospectively recorded from June of 1997 to October 2000. <h3>Results</h3> 366 patients were included, 40 of them (10.7%) were lost of follow-up,146 of the 336 who completed the study were diagnosed of idiopahatic uveitis (43.4%),70 (21%) had some type of spondyloarthopaty (30 patients were diagnosed in our uveitis clinic), 33 (9.8%) were secondary to infections (23 herpes, 6 toxoplasmosis,3 tuberculosis, 1 candida), 3 were masquerade syndromes (1 lung cancer and 2 linphoproliferative diseases), 6 (1.7%) were traumatic, 47 (14%) were ophtalmologic syndromes, 21 (6.25%) uveitis were secondary to other rheumatic diseases (8 Behçet diseases,8 Sarcoidosis,4 Sjögren's syndrome and one juvenile chronic arthritis) and 2 were TINU syndromes. <h3>Conclusion</h3> We have achieved the etyology of the uveitis in 56.6%. A greater percentage than those found in other series in which the diagnostic procedures have not been prestablished. In addition, it could have a better cost-effective impact and avoid the number of consultations between different specialists. We believe that this is the first study in which a clinical protocol of diagnostic procedures has been validated in patients with uveitis.
Combinatorial Administration of Pharmacological Inhibitors Targeting DNMT1 and KDM1A Produces Synergistic and Additive Increases in F Retiulocytes and γ-Globin Expression in Normal Baboons
Authors: Vinzon Ibanez, Kestis Vaitkus, Robert E. Molokie, Yogenthiran Saunthararajah, Donald Lavelle
Journal: Blood (2020)
Therapeutic Options in Hereditary Optic Neuropathies
Authors: Giulia Amore, Martina Romagnoli, Michele Carbonelli, Piero Barboni, Valerio Carelli, Chiara La Morgia
Journal: Drugs (2020)

Options for the effective treatment of hereditary optic neuropathies have been a long time coming. The successful launch of the antioxidant idebenone for Leber's Hereditary Optic Neuropathy (LHON), followed by its introduction into clinical practice across Europe, was an important step forward. Nevertheless, other options, especially for a variety of mitochondrial optic neuropathies such as dominant optic atrophy (DOA), are needed, and a number of pharmaceutical agents, acting on different molecular pathways, are currently under development. These include gene therapy, which has reached Phase III development for LHON, but is expected to be developed also for DOA, whilst most of the other agents (other antioxidants, anti-apoptotic drugs, activators of mitobiogenesis, etc.) are almost all at Phase II or at preclinical stage of research. Here, we review proposed target mechanisms, preclinical evidence, available clinical trials with primary endpoints and results, of a wide range of tested molecules, to give an overview of the field, also providing the landscape of future scenarios, including gene therapy, gene editing, and reproductive options to prevent transmission of mitochondrial DNA mutations.
Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology
Authors: Leonie Klompstra, Martha Kyriakou, Ekaterini Lambrinou, Massimo F. Piepoli, Andrew J.S. Coats, Alain Cohen‐Solal, Justien Cornelis, Barnabas Gellen, Elena Marques‐Sule, David Niederseer, Francesco Orso, Ewa Piotrowicz, Emeline M. Van Craenenbroeck, Maria Simonenko, Klaus K. Witte, Anna Wozniak, Maurizio Volterrani, Tiny Jaarsma
Journal: European Journal of Heart Failure (2020)

The aims of this paper were to provide an overview of available activity monitors used in research in patients with heart failure and to identify the key criteria in the selection of the most appropriate activity monitor for collecting, reporting, and analysing physical activity in heart failure research. This study was conducted in three parts. First, the literature was systematically reviewed to identify physical activity concepts and activity monitors used in heart failure research. Second, an additional scoping literature search for validation of these activity monitors was conducted. Third, the most appropriate criteria in the selection of activity monitors were identified. Nine activity monitors were evaluated in terms of size, weight, placement, costs, data storage, water resistance, outcomes and validation, and cut-off points for physical activity intensity levels were discussed. The choice of a monitor should depend on the research aims, study population and design regarding physical activity. If the aim is to motivate patients to be active or set goals, a less rigorously tested tool can be considered. On the other hand, if the aim is to measure physical activity and its changes over time or following treatment adjustment, it is important to choose a valid activity monitor with a storage and battery longevity of at least one week. The device should provide raw data and valid cut-off points should be chosen for analysing physical activity intensity levels. Other considerations in choosing an activity monitor should include data storage location and ownership and the upfront costs of the device.
Abstract 518: Phosphorylation of MK5 at Threonine-182 in the Activation Loop is Mediated by P38α/β in Cardiac Fibroblasts
Authors: Pramod Sahadevan, Sherin A Nawaito, Joelle Trepanier, Fatiha Sahmi, Louis Villeneuve, Matthias Gaestel, Bruce G Allen
Journal: Circulation Research (2020)

MAP kinase-activated protein kinase-5 (MK5) is a protein serine/threonine kinase involved in fibroblast function. MK5 is activated by phosphorylation at threonine-182 (Thr182): p38α/β, ERK3, and ERK4 have been implicated. We examined the phosphorylation of MK5 in adult cardiac ventricular fibroblasts. In serum-starved cardiac myofibroblasts (fibroblasts maintained on a plastic substrate), phospho-MK5 Thr182 (pThr182) immunoreactivity was predominantly nuclear. In response to serum, sorbitol, angiotensinII, TGFβ, or H 2 O 2 , pThr182 immunoreactivity both increased in intensity and relocated to the cytoplasm and the perinuclear region. In each case, the p38α/β inhibitor, SB203580, prevented both the increase in intensity and redistribution of pThr182 immunoreactivity. Incontrast, siRNA-mediated knockdown of ERK3 resulted in a diffuse cytosolic distribution of pThr182 immunoreactivity but failed to attenuate the increase in intensity. On Phos-tag PAGE, the electrophoretic mobility of phosphorylated proteins is reduced. Phos-tag PAGE resolved MK5 immunoreactivity from actively dividing myofibroblasts into several slower-migrating bands that were absent following 1) pretreatment with phosphoprotein phosphatase or 2) including EDTA in the Phos-tag gels. In serum-stimulated myofibroblasts, SB203580 reduced both the abundance of lower-mobility forms of MK5 on Phos-tag PAGE and the abundance of MK5 immunoreactivity in ERK3 immunoprecipitates. When fibroblasts were maintained on a compliant (8-kPa) substrate, and hence quiescent, the lower mobility forms of MK5 immunoreactivity were less abundant relative to myofibroblasts. Furthermore, in whole heart lysates from micesacrificed 8 weeks after constriction of the transverse aorta (TAC), Phos-tag PAGE revealed banding patterns consistent with increased MK5 phosphorylation relative to sham hearts. Taken together, these observations suggest: 1) p38α/β are the primarymediators of MK5 phosphorylation at Thr182 in cardiac fibroblasts, 2) ERK3 may be responsible for targeting activated MK5 to specific cytosolic sites, 3) Thr182 is not the only site at which MK5 is phosphorylated in vivo , and 4) MK5 phosphorylation increases with fibroblast activation.
Network Characteristics and Visualization of COVID-19 Outbreak in a Large Detention Facility in the United States — Cook County, Illinois, 2020
Authors: Uzay Kırbıyık, Alison M. Binder, Isaac Ghinai, Chad Zawitz, Rebecca Levin, Usha Samala, Michelle Bryant Smith, Jane Gubser, Bridgette Jones, Kate Varela, Josh Rafinski, Anne Fitzgerald, Peter Orris, Alex Bahls, Sharon Welbel, Connie Mennella, Stephanie R. Black, Paige A. Armstrong
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Correctional and detention facilities have been disproportionately affected by coronavirus disease 2019 (COVID-19) because of shared space and movement of staff members and detained persons within facilities (1,2).During March 1-April 30, 2020, at Cook County Jail in Chicago, Illinois, >900 COVID-19 cases were diagnosed across all 10 housing divisions, representing 13 unique buildings.† Movement within the jail was examined through network analyses and visualization, a field that examines elements within a network and the connections between them.This methodology has been used to supplement contact tracing investigations for tuberculosis and to understand how social networks contribute to transmission of sexually transmitted infections (3-5).Movements and connections of 5,884 persons (3,843 [65%] detained persons and 2,041 [35%] staff members) at the jail during March 1-April 30 were analyzed.A total of 472 (12.3%)COVID-19 cases were identified among detained persons and 198 (9.7%) among staff members.Among 103,701 shared-shift connections among staff members, 1.4% occurred between persons with COVID-19, a percentage that is significantly higher than the expected 0.9% by random occurrence alone (p<0.001),suggesting that additional transmission occurred within this group.The observed connections among detained persons with COVID-19 were significantly lower than expected (1.0% versus 1.1%, p<0.001) when considering only the housing units in which initial transmission occurred, suggesting that the systematic isolation of persons with COVID-19 is effective at limiting transmission.A network-informed approach can identify likely points of high transmission, allowing for interventions to reduce transmission targeted at these groups or locations, such as by reducing convening of staff members, closing breakrooms, and cessation of contact sports.All detained persons with data available for at least one bed assignment at Cook County Jail during March 1-April 30, 2020, were identified using records provided by Cook County Sheriff 's Office (CCSO), and Cermak Health Services.CCSO staff members who worked at least one shift at the jail during the same period were also included.A case of COVID-19 was defined as detection of SARS-CoV-2 by real-time reverse transcription-polymerase chain reaction (RT-PCR) in a
Abstract MP124: De-palmitoylation of Cysteine 202 of Cyclophilin-D by Calcium is Important for the Activation of the Permeability Transition Pore
Authors: Georgios Amanakis, Junhui Sun, Maria Fergusson, Chengyu Liu, Jeff D Molkentin, Elizabeth Murphy
Journal: Circulation Research (2020)

Cyclophilin-D (CypD) is a well-known regulator of the mitochondrial permeability transition pore (PTP), the main effector of cardiac ischemia/reperfusion (I/R) injury characterized by oxidative stress and calcium overload. However, the mechanism by which CypD activates PTP is poorly understood. Cysteine 202 of CypD (C202) is highly conserved across species and can undergo redox-sensitive post-translational modifications, such as S-nitrosylation and oxidation. To study the importance of C202, we developed a knock-in mouse model using CRISPR where CypD-C202 was mutated to a serine (C202S). Hearts from these mice are protected against I/R injury. We found C202 to be abundantly S-palmitoylated under baseline conditions while C202 was de-palmitoylated during ischemia in WT hearts. To further investigate the mechanism of de-palmitoylation during ischemia, we considered the increase of matrix calcium, oxidative stress and uncoupling of ATP synthesis from the electron transport chain. We tested the effects of these conditions on the palmitoylation of CypD in isolated cardiac mitochondria. The palmitoylation of CypD was assessed using a resin-assisted capture (Acyl-RAC). We report that oxidative stress (phenylarsenide) and uncoupling (CCCP) had no effect on CypD palmitoylation (p&gt;0.05, n=3 and n=7 respectively). However, calcium overload led to de-palmitoylation of CypD to the level observed at the end ischemia (1±0.10 vs 0.63±0.09, p=0.012, n=9). To further test the hypothesis that calcium regulates S-palmitoylation of CypD we measured S-palmitoylation of CypD in non-perfused heart lysates from global germline mitochondrial calcium uniporter knock-out mice (MCU-KO), which have reduced mitochondrial calcium and we found an increase in S-palmitoylation of CypD (WT 1±0.04 vs MCU-KO 1.603±0.11, p&lt;0.001, n=6). The data are consistent with the hypothesis that C202 is important for the CypD mediated activation of PTP. Ischemia leads to increased matrix calcium which in turn promotes the de-palmitoylation of CypD on C202. The now free C202 can further be oxidized during reperfusion leading to the activation of PTP. Thus, S-palmitoylation and oxidation of CypD-C202 possibly target CypD to the PTP, making them potent regulators of cardiac I/R injury.
Comparison of FLU-BU12 Conditioning with the Standard BU-CY Myeloablative Regimen in High-Risk Pediatric ACUTE Myeloid Leukemia Patients Undergoing Allogeneic STEM Cell Transplantation
Authors: Olesia V Paina, Zhemal Zarifovna Rakhmanova, Polina Valerievna Kozhokar, Anastasia S Frolova, Liubov A. Tsvetkova, Kirill Alexandrovich Ekushov, Inna Markova, Sergey N. Bondarenko, Elena V. Babenko, Aleksandr L. Alyanskiy, Ildar M Barkhatov, Elena Vladimirovna Semenova, Aleksandr D. Kulagin, Ivan S. Moiseev, Ludmila S Zubarovskaya
Journal: Blood (2020)
3D Liver Models: Biofabrication of Hepatic Constructs by 3D Bioprinting of a Cell‐Laden Thermogel: An Effective Tool to Assess Drug‐Induced Hepatotoxic Response (Adv. Healthcare Mater. 21/2020)
Authors: Manuele Gori, Sara M. Giannitelli, Miranda Torre, Pamela Mozetic, Franca Abbruzzese, Marcella Trombetta, Enrico Traversa, Lorenzo Moroni, Alberto Rainer
Journal: Advanced Healthcare Materials (2020)

In article number 2001163, Alberto Rainer and co-workers propose a semi-synthetic thermoresponsive hydrogel system for the direct-write bioprinting of hepatic cells. The resulting 3D model outperforms conventional 2D cultures in terms of liver-specific metabolism and susceptibility to a known hepatotoxic compound.
Correlation of multimodal <sup>18</sup>F-DOPA PET and conventional MRI with treatment response and survival in children with diffuse intrinsic pontine gliomas
Authors: Giovanni Morana, Domenico Tortora, Gianluca Bottoni, Matteo Puntoni, Gianluca Piatelli, Federica Garibotto, Salvina Barra, Flavio Giannelli, Angelina Cistaro, Mariasavina Severino, Antonio Verrico, Claudia Milanaccio, Maura Massimino, Maria Luisa Garrè, Andrea Rossi, Arnoldo Piccardo
Journal: Theranostics (2020)

To evaluate the contribution of 18 F-dihydroxyphenylalanine (DOPA) PET in association with conventional MRI in predicting treatment response and survival outcome of pediatric patients with diffuse intrinsic pontine gliomas (DIPGs).Methods: We retrospectively analyzed 19 children with newly diagnosed DIPGs who underwent 18 F-DOPA PET/CT and conventional MRI within one week of each other at admission and subsequent MRI follow-up.Following co-registration and fusion of PET and MRI, 18 F-DOPA uptake avidity and extent (PET tumor volume and uniformity) at admission, along with MRI indices including presence of ring contrast-enhancement, tumor volume at admission and at maximum response following first-line treatment, were evaluated and correlated with overall survival (OS).The association between 18 F-DOPA uptake tumor volume at admission and MRI tumor volume following treatment was evaluated.Statistics included Wilcoxon signed-rank and Mann-Whitney U tests, Kaplan-Meier OS curve and Cox analysis.Results: DIPGs with a 18 F-DOPA uptake Tumor/Striatum (T/S) ratio >1 presented an OS ≤ 12 months and lower degree of tumor volume reduction following treatment (p = 0.001).On multivariate analysis, T/S (p = 0.001), ring enhancement (p = 0.01) and the degree of MRI tumor volume reduction (p = 0.01) independently correlated with OS.In all patients, areas of increased 18 F-DOPA uptake overlapped with regions demonstrating more prominent residual components/lack of response following treatment.Conclusions: 18 F-DOPA PET provides useful information for evaluating the metabolism of DIPGs.T/S ratio is an independent predictor of outcome. 18F-DOPA uptake extent delineates tumoral regions with a more aggressive biological behaviour, less sensitive to first line treatment.
Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study
Authors: Emma Catherine Difilippo, Alejandro Ferrer, Laura Schultz-Rogers, Naseema Gangat, Shakila P Khan, Aref Al-Kali, Abhishek A. Mangaonkar, Animesh Pardanani, Michelle Elliot, Mark Litzow, William J Hogan, Alexandra P. Wolanskyj, Phuong L. Nguyen, Kaaren K. Reichard, Matthew T Howard, Rebecca L. King, Dong Chen, Rong He, David S. Viswanatha, Terra Lasho, Rajiv K. Pruthi, Pavel Pichurin, Teresa Kruisselbrink, Brendan Lanpher, Mark E Wylam, Jennifer L. Oliveira, Dusica Babovic-Vuksanovic, Horatiu Olteanu, Mrinal M. Patnaik
Journal: Blood (2020)
Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?
Authors: Jean-Marie Michot, Valérie Camara-Clayette, Cyril Quivoron, Alina Danu, Julien Lazarovici, David Ghez, Julien Rossignol, Capucine Baldini, Patricia Martin-Romano, Clementine Sarkozy, Andrea Varga, Helene Lecourt, Veronique Vergé, Sophie Cotteret, Peggy Dartigues-Cuillères, Christophe Massard, Vincent Ribrag
Journal: Blood (2020)
Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Authors: David G. Maloney, John Kuruvilla, Christopher P Fox, Guillaume Cartron, Daniel Li, Jens Hasskarl, Ashley Bonner, Yixie Zhang, Fei Fei Liu
Journal: Blood (2020)
A Systemic Review on Efficacy of Ibrutinib-Based Regimens for the Treatment of Waldenstrom Macroglobulinemia
Authors: Qasim Khurshid, Abdul Jabbar Dar, Muhammad Ali Mirza, Muhaddis Ejaz Ahmad, Ali Jaan, Sobia Aamir, Syed Maaz Abdullah, Richi Kashyap, Israr Khan, Waqas Khan, Sundas Ali, Arshia Akbar, Saad Javed, Fazeel Qamar, Faiz Anwer
Journal: Blood (2020)
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
Authors: Karine Clément, Erica van den Akker, Jesús Argente, Allison Bahm, Wendy K Chung, Hillori Connors, Kathleen De Waele, I Sadaf Farooqi, Julie Gonneau-Lejeune, Gregory Gordon, Katja Kohlsdorf, Christine Poitou, Lia Puder, James Swain, Murray Stewart, Guojun Yuan, Martin Wabitsch, Peter Kühnen, Patricia Pigeon-Kherchiche, Anna Flaus-Furmaniuk, Martin Bald, Christian Denzer, Julia von Schnurbein, Ozair Abawi, Ulrike Blume-Peytavi, Philipp Krabusch, Knut Mai, Dirk Schnabel, Susanna Wiegand, Christa E Flück, Esther Schulz, Egbert Voss, Natasa Bratina, Katja Weiss, Gabriel Á Martos-Moreno, Alban Danset, Paul Gougis, Béatrice Dubern, Karine Clément, Erica L.T. van den Akker, Jesús Argente, Allison L Bahm, Wendy K Chung, Hillori S Connors, Kathleen De Waele, Ismaa Sadaf Farooqi, Julie Gonneau-Lejeune, Gregory A Gordon, Christine Poitou, Lia Puder, James M Swain, Murray W Stewart, Goujun Yuan, Martin Wabitsch, Peter Kühnen
Journal: The Lancet Diabetes & Endocrinology (2020)
Impact of Significant Eosinophilia in Patients with Myelodysplastic Syndromes: Single Institution Experience
Authors: Salwa S Saadeh, Omar Alkharabsheh, Darci Zblewski, Mrinal M. Patnaik, Naseema Gangat, Kebede H. Begna, Hassan B. Alkhateeb, Michelle A. Elliott, Rong He, Phuong Nguyen, William J. Hogan, Mark R. Litzow, Aref Al-Kali
Journal: Blood (2017)
Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)
Authors: Liora M. Schultz, Christina Baggott, Snehit Prabhu, Holly Pacenta, Christine L Phillips, Jenna Rossoff, Heather Stefanski, Julie-An Talano, Amy Moskop, Steven P. Margossian, Michael R Verneris, Gary Douglas Myers, Nicole Karras, Patrick A. Brown, Muna Qayed, Michelle Hermiston, Prakash Satwani, Christa Krupski, Amy Keating, Rachel Wilcox, Cara A Rabik, Vanessa Fabrizio, Michael Kunicki, Vasant Chinnabhandar, A. Yasemin Goksenin, Kevin J. Curran, Crystal L. Mackall, Theodore W. Laetsch
Journal: Blood (2020)
NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in <i>In Vivo</i> Models of AML and ALL
Authors: Eliana Ruggiero, Dai Liu, Aaron Prodeus, Amy M Becker, Maxwell Foisey, Ishina Balwani, Ivy Dutta, Qingzhan Zhang, Simo M Arredouani, Mark McKee, Fabio Ciceri, Laura Sepp-Lorenzino, Chiara Bonini, Birgit C Schultes
Journal: Blood (2020)
The novel small-molecule TPN10456 inhibits Th17 cell differentiation and protects against experimental autoimmune encephalomyelitis
Authors: Cuixia Yang, Jie Lv, Xiangrui Jiang, Zhenglong Xiang, Ran Gong, Jiahua Xing, Guangyu Liu, Ling Xie, Kandireya Saimaier, Yan Zhang, Junjian Wang, Hu Shen, Juping Pan, Jingshan Shen, Changsheng Du
Journal: Cellular and Molecular Immunology (2020)